Aeolus Pharmaceuticals, Inc. (AOLS)

0,0000 -0,0001 (-99,00%) Ab 10:44AM EDT. Markt geöffnet.

Aeolus Pharmaceuticals, Inc.

26361 Crown Valley Parkway
Suite 150
Mission Viejo, CA 92691
United States
949-481-9825
https://www.aeoluspharma.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 4

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John L. Mcmanus	Chief Executive Officer and President	460,33k	N/A	1964
Mr. Christopher Stanley	Vice President of Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2016 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Corporate Governance

Aeolus Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.